Tarsus Pharmaceuticals, Inc. TARS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s EBITDA margin?
- Tarsus Pharmaceuticals, Inc. (TARS) reported EBITDA margin of -9.2% in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s EBITDA margin changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s EBITDA margin increased by 80.1% year-over-year, from -46.1% to -9.2%.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s EBITDA margin?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s EBITDA margin has grown at a -7.3% compound annual growth rate (CAGR), from -20.8% to -15.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.